GHGuardant Health, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet and clean books, but heavy debt (CCC) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$30.7M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -91% · now 11% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can GH take a bad year?
The deepest fall in GH's price history on file is −91%; it is 11% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Altman Z-score
- 3.76
Altman Z-score · safe zone, above 3
- Cash runway
- 4.4 years
Cash runway · burning $60M a quarter at the current rate
- Annualised volatility
- 61%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $1.50B
- Cash and short-term investments
- $1.05B
- Net debt
- $449M
- EBITDA, trailing twelve months
- −$432M
- Operating profit, trailing twelve months
- −$470M
- Annualised volatilitytwo years of daily moves
- 61%
- Worst drawdown on file
- −91%
- Below its 52-week high
- 11%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Diagnostics & Research
Ranks #18 of 21 by RyuScore